Univariate analysis for CTLA-4 polymorphisms and HSCT outcome
| . | Overall survival . | aGVHD II-IV . | Relapse . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | |
| −1722 CC/CT | .454 | 1.16 | 0.78-1.73 | .112 | 0.74 | 0.52-1.07 | .523 | 1.16 | 0.73-1.85 |
| −1661 AG/GG | .538 | 1.11 | 0.79-1.55 | .679 | 1.07 | 0.76-1.50 | .268 | 1.26 | 0.84-1.88 |
| −318 CT/TT | .393 | 0.83 | 0.55-1.26 | .882 | 0.97 | 0.65-1.44 | .854 | 0.96 | 0.61-1.50 |
| +49 AG/GG | .019 | 1.47 | 1.06-2.02 | .072 | 0.75 | 0.55-1.02 | .276 | 1.22 | 0.85-1.75 |
| CT60 AG/GG | .016 | 1.57 | 1.09-2.26 | .108 | 0.77 | 0.56-1.06 | .099 | 1.41 | 0.93-2.12 |
| . | Overall survival . | aGVHD II-IV . | Relapse . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | |
| −1722 CC/CT | .454 | 1.16 | 0.78-1.73 | .112 | 0.74 | 0.52-1.07 | .523 | 1.16 | 0.73-1.85 |
| −1661 AG/GG | .538 | 1.11 | 0.79-1.55 | .679 | 1.07 | 0.76-1.50 | .268 | 1.26 | 0.84-1.88 |
| −318 CT/TT | .393 | 0.83 | 0.55-1.26 | .882 | 0.97 | 0.65-1.44 | .854 | 0.96 | 0.61-1.50 |
| +49 AG/GG | .019 | 1.47 | 1.06-2.02 | .072 | 0.75 | 0.55-1.02 | .276 | 1.22 | 0.85-1.75 |
| CT60 AG/GG | .016 | 1.57 | 1.09-2.26 | .108 | 0.77 | 0.56-1.06 | .099 | 1.41 | 0.93-2.12 |